| | 486460-32-6 Basic information More.. |
| Product Name: | Sitagliptin | | Synonyms: | Sitagliptin;(3R)-3-AMino-1-[3-(trifluoroMethyl)-5,6,7,8-tetrahydro-1,2,4-riazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-rifluorophenyl) butan-1-one;Sitagliptin-D4 HCL;Hsdb 7516;C53323300;Metformin / sitagliptin;Metformin hydrochloride mixture with sitagliptin phosphate;Metformin mixture with sitagliptin | | CAS: | 486460-32-6 | | MF: | C16H15F6N5O | | MW: | 407.31 | | EINECS: | 690-730-1 | | Mol File: | 486460-32-6.mol |  |
Use
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a first-in-class oral
drug launched for the treatment of type 2 diabetes. It acts by slowing the
inactivation of incretins, which are endogenous peptides involved in the physiologic
regulation of glucose homeostasis. Incretin hormones, including glucagonlike
peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),
are released by the intestine throughout the day, and levels are increased in
response to a meal. When blood glucose concentrations are normal or elevated,GLP-1 and GIP increase the synthesis and release of insulin from pancreatic b
cells via intracellular signaling pathways involving cAMP. GLP-1 also lowers
glucagon secretion from pancreatic αcells, which leads to reduced hepatic
glucose production.
- Sitagliptin
-
- US $0.00-0.00 / Kg/Bag
- 2024-09-19
- CAS:486460-32-6
- Min. Order: 1Kg/Bag
- Purity: 98.5% up
- Supply Ability: 20tons
- Sitagliptin
-
- US $100.70 / KG
- 2024-09-19
- CAS:486460-32-6
- Min. Order: 10KG
- Purity: 99%
- Supply Ability: 10000kg
- Sitagliptin
-
- US $0.00-0.00 / g
- 2024-09-19
- CAS:486460-32-6
- Min. Order: 10g
- Purity: 99% HPLC
- Supply Ability: 10000
|
|
486460-32-6
Recommend Suppliers |
|